Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Way W. Wong"'
Autor:
Stephen M.F. Jamieson, Peter Tsai, Maria K. Kondratyev, Pratha Budhani, Arthur Liu, Neil N. Senzer, E. Gabriela Chiorean, Shadia I. Jalal, John J. Nemunaitis, Dennis Kee, Avik Shome, Way W. Wong, Dan Li, Nooriyah Poonawala-Lohani, Purvi M. Kakadia, Nicholas S. Knowlton, Courtney R.H. Lynch, Cho R. Hong, Tet Woo Lee, Reidar A. Grénman, Laura Caporiccio, Trevor D. McKee, Mark Zaidi, Sehrish Butt, Andrew M.J. Macann, Nicholas P. McIvor, John M. Chaplin, Kevin O. Hicks, Stefan K. Bohlander, Bradly G. Wouters, Charles P. Hart, Cristin G. Print, William R. Wilson, Michael A. Curran, Francis W. Hunter
Publikováno v:
JCI Insight, Vol 8, Iss 4 (2023)
Externí odkaz:
https://doaj.org/article/b8265d5c0ed44e2583f6823d2b9a7cc0
Autor:
Lydia P. Liew, Avik Shome, Way W. Wong, Cho R. Hong, Kevin O. Hicks, Stephen M. F. Jamieson, Michael P. Hay
Publikováno v:
Molecules, Vol 28, Iss 11, p 4457 (2023)
The role of hypoxic tumour cells in resistance to radiotherapy, and in suppression of immune response, continues to endorse tumour hypoxia as a bona fide, yet largely untapped, drug target. Radiotherapy innovations such as stereotactic body radiother
Externí odkaz:
https://doaj.org/article/4764aa3eb15346ccaeda89c53387ec2a
Autor:
Hay, Lydia P. Liew, Avik Shome, Way W. Wong, Cho R. Hong, Kevin O. Hicks, Stephen M. F. Jamieson, Michael P.
Publikováno v:
Molecules; Volume 28; Issue 11; Pages: 4457
The role of hypoxic tumour cells in resistance to radiotherapy, and in suppression of immune response, continues to endorse tumour hypoxia as a bona fide, yet largely untapped, drug target. Radiotherapy innovations such as stereotactic body radiother
Autor:
Gib Bogle, William R. Wilson, Michael P. Hay, Praju Vikas Anekal, Kevin O. Hicks, Benjamin D. Dickson, Way W. Wong, Chantal D. Buckley, Cho R. Hong
Publikováno v:
Radiotherapy and Oncology. 166:162-170
Background and purpose Inhibitors of DNA-dependent protein kinase (DNA-PK) are effective radiation sensitisers in preclinical tumours, but little is known about risks of normal tissue radiosensitisation. Here, we evaluate radiosensitisation of head a
Autor:
Dean C. Singleton, Lydia P. Liew, Stephen M. F. Jamieson, Michael P. Hay, Way W. Wong, Gary J. Cheng
Publikováno v:
Chemistry – An Asian Journal. 14:1238-1248
Tumour hypoxia plays an important role in tumour progression and resistance to therapy. Under hypoxia unfolded proteins accumulate in the endoplasmic reticulum (ER) and this stress is relieved through the protein kinase R-like ER kinase (PERK) signal
Autor:
William R. Wilson, Ralph J. Stevenson, Cho R. Hong, Stephen M. F. Jamieson, Wen Qi, Avik Shome, Yongchuan Gu, Robert F. Anderson, Way W. Wong, Muriel Bonnet, Michael P. Hay, Jingli Wang, Kevin O. Hicks, Frederik B. Pruijn, Lydia P. Liew
Publikováno v:
Journal of Medicinal Chemistry. 61:1241-1254
Innovations in the field of radiotherapy such as stereotactic body radiotherapy, along with the advent of radio-immuno-oncology, herald new opportunities for classical oxygen-mimetic radiosensitizers. The role of hypoxic tumor cells in resistance to
Autor:
William R. Wilson, Liew P. Liew, Way W. Wong, Cho R. Hong, Michael P. Hay, Gary J. Cheng, Benjamin D. Dickson, Stephen M. F. Jamieson
Publikováno v:
Clinical Cancer Research. 27:PO-018
Inhibition of the repair of radiation-induced DNA double strand breaks offers the potential to sensitize tumors to radiation therapy. DNA-dependent protein kinase (DNA-PK) is a well validated target for radiosensitisation, but inhibition also has the
Autor:
William R. Wilson, Michael P. Hay, Benjamin D. Dickson, Gary J. Cheng, Francis W. Hunter, Barbara Lipert, Lydia P. Liew, Rosanna K. Jackson, Yongchuan Gu, Way W. Wong
Publikováno v:
Biochemical pharmacology. 169
DNA-dependent protein kinase (DNA-PK) plays a key role in repair of radiation-induced DNA double strand breaks (DSB) by non-homologous end-joining. DNA-PK inhibitors (DNA-PKi) are therefore efficient radiosensitisers, but normal tissue radiosensitisa
Publikováno v:
Molecules
Volume 24
Issue 8
Molecules, Vol 24, Iss 8, p 1559 (2019)
Volume 24
Issue 8
Molecules, Vol 24, Iss 8, p 1559 (2019)
Poly(ADP-ribose)polymerase (PARP) inhibitors (PARPi) have recently been approved for the treatment of breast and ovarian tumors with defects in homologous recombination repair (HRR). Although it has been demonstrated that PARPi also sensitize HRR com
Autor:
Reidar Grénman, John Nemunaitis, Mark Zaidi, William R. Wilson, Courtney R. H. Lynch, Trevor D. McKee, Cho R. Hong, Peter Tsai, Charles P. Hart, Dennis Kee, Purvi M. Kakadia, John M. Chaplin, Tet Woo Lee, Bradly G. Wouters, Stephen M. F. Jamieson, Arthur Liu, Nicholas P. McIvor, Francis W. Hunter, Shadia I. Jalal, Cristin G. Print, Nicholas Knowlton, E. Gabriela Chiorean, Nooriyah Poonawala-Lohani, Way W. Wong, Kevin O. Hicks, Dan Li, Laura Caporiccio, Neil Senzer, Avik Shome, Michael A. Curran, Andrew Macann, Pratha Budhani, Maria Kondratyev, Stefan K. Bohlander, Sehrish Butt
Publikováno v:
JCI Insight. 3(16)
Evofosfamide (TH-302) is a clinical-stage hypoxia-activated prodrug of a DNA-crosslinking nitrogen mustard that has potential utility for human papillomavirus (HPV) negative head and neck squamous cell carcinoma (HNSCC), in which tumor hypoxia limits